How evidence-based are current guidelines for managing patients with peptic ulcer bleeding?

Area of Science:

• Gastroenterology
• Endoscopic Procedures
• Pharmacology

Background:

• Current guidelines advocate dual endoscopic therapy and high-dose intravenous proton pump inhibitors (PPIs) for bleeding peptic ulcers with major stigmata.
• This review critically evaluates the evidence behind these recommendations.

Purpose of the Study:

• To assess the superiority of continuous infusion PPIs over other regimens.
• To determine the necessity of adding a second endoscopic hemostatic procedure to epinephrine injection.

Main Methods:

• Systematic literature searches were conducted on PubMed, EMBASE, and the Cochrane library.
• Evidence for PPI efficacy, dosage, and administration route was analyzed.
• Studies comparing epinephrine monotherapy with dual endoscopic therapy were reviewed.

Main Results:

• Proton pump inhibitors (PPIs) show a clear benefit over H2-receptor antagonists or placebo in peptic ulcer bleeding.
• PPI efficacy is not dependent on intensive dosage or intravenous administration.
• Evidence for adding a second endoscopic modality to epinephrine is inconclusive and depends on follow-up protocols.

Conclusions:

• High-dose PPI infusion and dual endoscopic therapy are not definitively superior for all patients with bleeding peptic ulcers.
• Epinephrine monotherapy combined with standard-dose PPIs is appropriate for the majority of patients.
• Further research is needed to clarify optimal management strategies.